Haystack oncology and universitÉ de montrÉal's affiliated hospital research centre, the crchum, to deploy haystack mrd™ technology in research study for metastatic colorectal cancer

Baltimore, md. and montreal , july 29, 2024 /prnewswire/ -- haystack oncology, a quest diagnostics (nyse: dgx) company, announced today a research collaboration with dr. simon turcotte, hepatopancreatobiliary surgeon and scientist at universitÉ de montrÉal's affiliated hospital research centre, the crchum, to utilize haystack oncology's personalized mrd technology (haystack mrd™) to evaluate treatment effectiveness in patients with metastatic colorectal cancer (mcrc) with metastases confined to the liver.
DGX Ratings Summary
DGX Quant Ranking